Jaya Biosciences has received from the United States Patent and Trademark Office (USPTO) US Patent No. 12,460,262, entitled “METHODS OF DETECTING, PREVENTING, REVERSING, AND TREATING NEUROLOGICAL DISEASES.” This patent issuance marks a significant expansion of JayaBio’s global Intellectual Property (IP) estate following prior patent issuances in Japan, China, and Singapore, and strengthens protection for its pioneering approach to lysosomal enzyme gene-based interventions in Alzheimer’s disease and other neurodegenerative conditions. The patent covers proprietary methods for detecting, preventing, reversing, and treating neurological diseases linked to heterozygous mutations in lysosomal enzyme genes—genetic variants shown to increase susceptibility to adult-onset neurodegeneration, including Alzheimer’s disease.

“This granted US patent represents an important milestone for JayaBio. It underscores our commitment to addressing the genetic and molecular underpinnings of Alzheimer’s disease and further validates the novelty and therapeutic potential of our precision medicine gene therapy platform. The addition of US patent protection reinforces the company’s strategic position in one of the world’s most important biotechnology markets and enables us to pursue future partnerships and development opportunities,” said Pawel Krysiak, President and Chief Executive Officer, Jaya Biosciences.

JayaBio’s IP portfolio is licensed from Washington University in St Louis, Missouri, where investigators discovered that mutations in lysosomal enzyme genes represent key risk factors for adult-onset neurological disease, including Alzheimer’s disease.

“The US market is critical for both the scientific validation and commercialisation of innovative Alzheimer’s disease therapies. This patent further secures our foundational Intellectual Property and strengthens our position as a leader in the emerging field of gene therapy for lysosomal dysfunction–associated neurodegeneration,” added Eric Grinstead, Chief Commercial Officer, Jaya Biosciences.

Human genetic analyses showed that deleterious variants in several lysosomal enzyme genes are enriched in the Alzheimer’s population compared to matched controls.

“These findings expand our understanding of the genetic factors associated with neurodegeneration in adults. Carriers of lysosomal enzyme gene defects were historically considered unaffected throughout life, but our data demonstrate a strong association between carrier status and adult-onset neurological disease. This discovery represents a paradigm shift in how we view genetic risk and intervention strategies for Alzheimer’s and related disorders,” said Professor Mark Sands, Chair, Scientific Advisory Board, JayaBio and Professor, Washington University School of Medicine.